Samsung BioLogics seals coveted $2bn IPO
Samsung BioLogics Co has priced its IPO at the top on the back of a surge in chunky orders, raising W2.25tr ($2.0bn) in South Korea's largest float since 2010.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: